IBSA expands its product portfolio for the osteoarticular area

25 May 2021

Osteoarthritis (OA) is a chronic joint disease characterised by degenerative processes, and the most common rheumatic condition worldwide, affecting 10% of the general adult population and 50% of all people over 60 years of age. It usually affects the joints most subject to wear and weightbearing, such as the lumbar vertebrae and the knees.
Osteoarthritic joints present characteristic changes in the cartilage, leading to pain, stiffness and loss of function. OA is caused by a great many factors and is often associated with aging and excess weight. However, it can also be the result of lesions and injuries, hereditary factors and abuse or lack of exercise.

IBSA expands its product portfolio for the osteoarticular area

As is emphasised by the latest ESCEO* guidelines, prevention is of paramount importance and involves lifestyle intervention and treatment of the osteoarthritis from the very earliest stages. The management and treatment of this condition is not simple and requires a flexible and gradual clinical and therapeutic approach, based on the severity and evolution of the disease, for which the gold-standard treatment is constituted by symptomatic slow-acting drugs of osteoarthritis (SYSADOA), which include substances with a favourable safety profile that are also essential constituents of joint cartilage, such as prescription chondroitin sulphate (CS) and glucosamine.
IBSA has always been committed to the osteoarticular area, with innovative solutions for each stage of the disease’s progression, ranging from oral treatments to products for injection containing hyaluronic acid. As a matter of fact, the Company is a world leader in the development of products containing hyaluronic acid.
In order to satisfy clinical needs and improve patients’ treatment compliance and adherence, IBSA’s Research & Development Group has developed a novel oral gel chondroitin sulphate formulation for once-daily administration, with a further expansion of its product portfolio for the osteoarticular area.

* European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Share on your social media